India, June 16 -- Global pharmaceutical company Lupin Limited has entered into a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for the commercialization of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule, in China. The medication is used for managing chronic obstructive pulmonary disease (COPD).
Under the terms of the agreement, SUP will handle regulatory approvals and commercial distribution in China, while Lupin will act as the marketing authorization holder and continue manufacturing the product. Tiotropium DPI is widely recognized for improving lung function and enhancing the quality of life for patients with respiratory ailments.
"This collaboration marks a significant step in expanding our presence in Ch...